A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting now · Phase 3
Conditions studied: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
In brief
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Key facts
- Study ID
- NCT04786262
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 52
- Starts
- 2021-03-29
- Expected to finish
- 2030-06-30
- Last updated by the study team
- 2026-06-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Newcastle upon Tyne Hospitals NHS Foundation Trust — Newcastle upon Tyne, United Kingdom (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- UHealth Diabetes Research Institute — Miami, Florida, United States (enrolling)
- Cardiovascular, Metabolic Medicine and Sciences, King's College London — London, United Kingdom (enrolling)
- City of Hope — Duarte, California, United States (enrolling)
- University of Chicago — Chicago, Illinois, United States (enrolling)
- Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- University of Pittsburgh Medical Center Montefiore — Pittsburgh, Pennsylvania, United States (enrolling)
- Baylor Scott and White Research Institute — Dallas, Texas, United States (enrolling)
- VCU Medical Center, Richmond — Richmond, Virginia, United States (enrolling)
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
- University of Alberta, Edmonton — Edmonton, Canada (enrolling)
- McGill University Health Centre — Montreal, Canada (enrolling)
- Toronto General Hospital (TGH) — Toronto, Canada (enrolling)
- Vancouver General Hospital — Vancouver, Canada (enrolling)
- CHU Lille — Lille, France (enrolling)
- Centre de recherche en Biomédecine de Strasbourg — Strasbourg, France (enrolling)
- Dresden Center for Islet Transplantation — Dresden, Germany (enrolling)
- IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)
- Leiden University — Leiden, Netherlands (enrolling)
- Oslo University Hospital — Oslo, Norway (enrolling)
- King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology — Riyadh, Saudi Arabia (enrolling)
- King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology — Riyadh, Saudi Arabia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.